000 | 02165nam a22001817a 4500 | ||
---|---|---|---|
003 | OSt | ||
005 | 20160506120752.0 | ||
008 | 160401b xxu||||| |||| 00| 0 eng d | ||
040 | _cNational Acoustic Laboratories | ||
100 | _aEnglish, Ruth | ||
245 | _aFitting recommendations and clinical benefit associated with use of the NAL-NL2 hearing aid prescription in Nucleus cochlear implant recipients | ||
520 | 3 | _aObjective: For a group of cochlear implant recipients, who use hearing aids in the contralateral ear, the benefit of NAL-NL2 relative to a recipients’ own prescription was assessed. Whether there was a preferred frequency response and/or gain deviation from NAL-NL2 was then investigated. Design: Speech recognition and self-reported ratings of benefit were examined for the recipients’ own prescription compared to the NAL-NL2 prescription, in the bimodal and hearing-aid alone conditions. Paired-comparison of hearing-aid frequency response was conducted with default NAL-NL2 and two variants, a low frequency boost or cut. Using a loudness balancing procedure, the hearing-aid gain required to achieve equal loudness between the devices was measured. Study sample: Sixteen adults with post-lingual hearing loss. Results: A 22% increase in group median word score in quiet with use of NAL-NL2 in the hearing-aid alone condition. In the bimodal condition there was no improvement with NAL-NL2. Default NAL-NL2 frequency response was preferred by 67% of participants. For 56% of participants, the preferred gain to achieve loudness balance across bimodal devices was within 5-dB of prescribed values. Conclusions: The NAL-NL2 prescription provides a high level of clinical performance, and an acceptable frequency response and gain for most participants. | |
650 | _aCochlear implant; bimodal; acoustic hearing; hearing-aid prescription | ||
700 | _aKerrie Plant ...[et.al.] | ||
773 | 0 |
_g2016; Early Online: 1–6 _tInternational Journal of Audiology |
|
856 | _uhttp://dspace.nal.gov.au/xmlui/bitstream/handle/123456789/346/Fitting%20recommendations%20and%20clinical%20benefit.pdf?sequence=1&isAllowed=y | ||
942 |
_2udc _cARTICLE |
||
999 |
_c2537 _d2537 |